Skip to content
10-Q

Quarterly Report

Neurogene Inc. NGNE

0001404644-26-000037

← back to feed
Filed
May 12, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 8, 2026 15.8M sh
Shares Diluted Q1 2026 · Mar 31, 2026 22.31M sh
Shares Diluted Q1 2026 · Mar 31, 2025 21M sh
Capex Q1 2026 · Mar 31, 2026 $281K
Capex Q1 2026 · Mar 31, 2025 $780K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$26.12M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$20.77M
Short Term Investments Q1 2026 · Mar 31, 2026 $119.02M
Short Term Investments Q1 2026 · Dec 31, 2025 $165.17M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $124.16M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $103.85M
Stockholders Equity Q1 2026 · Mar 31, 2026 $237.78M
Stockholders Equity Q1 2026 · Dec 31, 2025 $264.89M
Stockholders Equity Q1 2026 · Mar 31, 2025 $291.8M
Stockholders Equity Q1 2026 · Dec 31, 2024 $310.38M
Current Liabilities Q1 2026 · Mar 31, 2026 $18.87M
Current Liabilities Q1 2026 · Dec 31, 2025 $16.41M
Total Liabilities Q1 2026 · Mar 31, 2026 $25.36M
Total Liabilities Q1 2026 · Dec 31, 2025 $23.72M
Current Assets Q1 2026 · Mar 31, 2026 $246.75M
Current Assets Q1 2026 · Dec 31, 2025 $271.77M
Total Assets Q1 2026 · Mar 31, 2026 $263.14M
Total Assets Q1 2026 · Dec 31, 2025 $288.6M
Eps Diluted Q1 2026 · Mar 31, 2026 −$1.39
Eps Diluted Q1 2026 · Mar 31, 2025 −$1.08
Eps Basic Q1 2026 · Mar 31, 2026 −$1.39
Eps Basic Q1 2026 · Mar 31, 2025 −$1.08
Sga Expense Q1 2026 · Mar 31, 2026 $8.2M
Sga Expense Q1 2026 · Mar 31, 2025 $8.16M
Rd Expense Q1 2026 · Mar 31, 2026 $25.15M
Rd Expense Q1 2026 · Mar 31, 2025 $17.76M
Net Income Q1 2026 · Mar 31, 2026 −$30.93M
Net Income Q1 2026 · Mar 31, 2025 −$22.65M
Operating Income Q1 2026 · Mar 31, 2026 −$33.35M
Operating Income Q1 2026 · Mar 31, 2025 −$25.92M